Cantor Fitzgerald analyst Kristen Kluska downgraded Skye Bioscience (SKYE) to Neutral from Overweight with a price target of $2, down from $14. Skye Biosciences reported “disappointing” 26-week Phase 2a data for nimacimab in obesity, showing 1.52% weight loss int he monotherapy arm compared to 0.26% for placebo, significantly below the 5%-8% weight loss the company previously set expectations around, the analyst tells investors in a research note. The safety bar was met and the combination therapy did reach statistical significance, and Skye believes they have found the problem, Cantor says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE:
- Skye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald
- Skye Bioscience Reveals Phase 2a Study Results
- Why Is Skye Bioscience Stock Down 60% Today?
- Skye Bioscience says nimacimab did not meet primary endpoint in CBeyond study
- Buy Rating for Skye Bioscience: Nimacimab’s Potential in Obesity Treatment Market